Janus Henderson Group plc Reports New 5.5% Stake in Edgewise Therapeutics, Inc. (EWTX)

Janus Henderson Group plc filed a Schedule 13G on May 15, 2026, reporting a new 5.5% stake in Edgewise Therapeutics, Inc. (EWTX). As of the event date on March 31, 2026, the investment firm holds 5,915,556 shares of common stock. Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over the shares on behalf of various managed portfolios. The filing indicates that the shares are held in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reported holdings reflect shared voting and dispositive power over the entire 5,915,556 shares. This position represents a significant increase from a previous ownership level of 0.0%, establishing Janus Henderson as a major institutional shareholder in the Boulder, Colorado-based biopharmaceutical company.